Affordability vs. Assurance: The Hidden Risks of Discount Weight-Loss Drugs

AURORA, Colo. – July 17, 2026 – The era of widespread shortages for blockbuster GLP-1 weight-loss drugs like Wegovy and Zepbound has officially ended, but a sprawling, high-stakes shadow market for their compounded alternatives is not only surviving—it's thriving. New research from the University of Colorado Anschutz reveals a troubling landscape where affordability collides with quality assurance, leaving some patients unknowingly exposed to products from pharmacies with concerning regulatory histories.

The study, published today in JAMA Health Forum, uncovers a market that has proven far more resilient than experts predicted. Using a "secret shopper" approach, researchers found that numerous weight-loss clinics and medical spas continue to aggressively market and sell compounded versions of semaglutide and tirzepatide. More alarmingly, the investigation traced some of these products back to suppliers lacking the necessary licenses for sterile compounding or those with recent disciplinary actions marring their records.

"Our findings suggest this market didn't shrink after the shortages ended as many expected," said lead author Michael J. DiStefano, PhD, MBE, an assistant professor at the CU Anschutz Skaggs School of Pharmacy and Pharmaceutical Sciences. "Instead, it has remained remarkably robust, raising important questions about how these products are regulated and how patients can know whether they're receiving medications that meet appropriate quality standards."

The Post-Shortage Pivot

During the peak of GLP-1 shortages, federal regulations temporarily permitted pharmacies to compound, or create custom-mixed versions of, these high-demand drugs. This was a crucial stopgap for patients. The CU Anschutz researchers sought to understand what happened when the supply of brand-name drugs stabilized and the FDA resumed enforcement against routine copies of commercially available products.

Instead of a market collapse, they discovered a strategic pivot. The investigation, which targeted 75 brick-and-mortar clinics and medical spas in Oklahoma and West Virginia, found that many compounded products now contain added ingredients, such as vitamin B12 or the amino acid levocarnitine. These additions are often marketed as "individualized formulations" that enhance energy or support weight loss. In reality, they may serve a different purpose: creating a product that is technically different from the FDA-approved version, thereby attempting to sidestep regulations that prohibit making "essentially copies" of commercial drugs.

"One concern is whether we're seeing clinically meaningful personalization or changes that primarily allow compounded products to remain on the market," DiStefano noted. "For many of these added ingredients, we simply don't have good evidence showing they improve safety or effectiveness." The FDA has echoed these concerns, warning that such additives lack evidence and could even cause harm through unknown ingredient interactions.

A Question of Quality and Safety

The study's most significant red flag is not the additives, but the source. Among 23 compounding pharmacies identified as suppliers to the clinics, researchers found that four lacked licenses for sterile compounding. Several others had recent FDA warning letters or disciplinary actions from state pharmacy boards related to their sterile compounding practices.

Sterile compounding is a non-negotiable standard for any injectable medication. It involves preparing drugs in a highly controlled, contaminant-free environment to prevent the introduction of dangerous microorganisms. Failure to adhere to these strict protocols, outlined in guidelines like USP , can turn a therapeutic drug into a vector for severe infections, sepsis, or worse. The public health risks are not theoretical; past outbreaks, such as a deadly fungal meningitis crisis linked to contaminated compounded steroids, serve as a stark reminder of the stakes.

Beyond contamination, major obesity care organizations have voiced a chorus of concerns about compounded GLP-1s. These products are not FDA-approved, meaning their purity, potency, and stability are unverified. Reports submitted to the FDA highlight a range of adverse events, including dosing errors from confusing multi-dose vials, severe gastrointestinal issues, and reactions to unapproved salt forms of the active ingredients, which are chemically different from those in brand-name drugs and have not been tested for safety.

The Patient’s Dilemma

Driving this billion-dollar shadow market is a simple, powerful force: cost. With list prices for brand-name GLP-1s often exceeding $1,000 per month and inconsistent insurance coverage, many patients feel they have no other choice. Compounded versions offer a lifeline, providing access to transformative obesity treatment at a fraction of the price.

This creates a profound ethical dilemma. As DiStefano emphasized, patients should not have to choose between affordability and quality. Yet, that is the precise choice many face. The rise of direct-to-consumer telehealth platforms and med spas has further complicated the landscape, with some online sellers prescribing these medications with little to no meaningful interaction with a clinician. A separate "secret shopper" study by Yale researchers found that many websites prescribing GLP-1s required no live consultation, shipping drugs directly to consumers after they filled out a simple form.

"Patients are caught in the middle," one anonymous public health advocate stated. "They are desperate for treatments that work, but the system is forcing them to gamble on products with unknown quality and sourcing." Major patient advocacy groups, including the Obesity Action Coalition and The Obesity Society, now formally recommend against the use of compounded alternatives, urging patients and providers to stick to FDA-approved, evidence-based care.

A Regulatory Tightrope

Regulators are not sitting idle. The FDA has intensified its crackdown, issuing dozens of warning letters to telehealth companies for misleading marketing and to distributors for illegally supplying active pharmaceutical ingredients to compounders. The agency has also proposed excluding semaglutide and tirzepatide from the "bulks list," a move that would severely restrict large-scale compounding of these drugs when they are not in shortage.

However, the sheer scale and diffuse nature of the market present an immense enforcement challenge for both federal and state authorities. The CU Anschutz study highlights the urgent need for "regulatory innovation"—new approaches that can protect public health without completely shutting down an important avenue of access for patients.

For now, the burden falls heavily on clinicians and patients. The researchers hope their findings encourage a more critical dialogue. They urge patients to ask pointed questions: Where does this medication come from? Is the compounding pharmacy licensed for sterile production? Can you verify its regulatory record? In the complex intersection of business, innovation, and health, transparency is the first, most critical step toward ensuring patient safety.